Navigation Links
Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
Date:12/7/2010

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after receiving a median of five prior lines of therapy (corresponding to a median of 13 anti-myeloma agents) and whose disease was refractory to their last therapeutic regimen. In addition, patients enrolled in the study had progressive disease upon entering the trial.  The clinical benefit rate (CBR) (minimal response or greater) in the study population was 34.2 percent.  The median overall survival (OS) was 15.5 months. Overall survival for responding patients (greater than or equal to minimal response) has not yet been reached; however, based on current data is expected to exceed 19 months.

Seventy-seven percent of patients had grade 1/2 peripheral neuropathy (PN) upon entry into the study.  New or worsening of PN was uncommon and Grade 3 PN occurred in less than 1 percent of patients. There were no Grade 4 PN events. A subset analysis of patients with PN (n= 202) on study was also presented at ASH.  Efficacy responses in patients with baseline PN were comparable to those seen in the full study population with an ORR of 24 percent and CBR of 34 percent. Based on the full 003-A1 results, Onyx plans to submit a New Drug Application (NDA) filing as early as mid-2011 for potential accelerated approval in the U.S.

These data are being presented today at the 52nd American Society of Hematology Annual Meeting in Orlando by David Siegel, M.D., Ph.D., Division Chief for Myelo
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Atlanta, GA (PRWEB) May 17, 2013 ... Obstetrics, Gynecology, and Women’s Health at the Albert Einstein ... of Oncology at the Montefiore Medical Center. He ... Einstein Cancer Center and leads the Einstein Breast Cancer ... focused on translational breast cancer research. He also serves ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... 17, 2013 •    First of its kind ... sustainability ,     New facility will help solve crop ... Syngenta unveiled its new crop research facility ... RTP Innovation Center. The first of its kind, $72 ... any agricultural climate and precisely measure plant inputs – ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3
... flashPAGE Fractionator System , , ... The flashPAGE Fractionator System is the , fastest, easiest, and ... acids. Unlike traditional Polyacrylamide Gel Electrophoresis (PAGE), , which was ... Fractionator System is designed and optimized for the purification of RNA , ...
... The RiboPure-Blood Kit recovers , ... , ... expression profiles better than competing , technologies ... Extracting RNA from Blood , ...
... No longer must you endure the high cost , ... siRNA. The new Silencer siRNA Construction Kit , ... can expand , your capacity for large siRNA ... of the same gene can be screened for a fraction of the , ...
Cached Biology Technology:Ultra-Fast Purification of Small Nucleic Acids 2Ultra-Fast Purification of Small Nucleic Acids 3Ultra-Fast Purification of Small Nucleic Acids 4Ultra-Fast Purification of Small Nucleic Acids 5Total RNA from Whole Blood for Expression Profiling 2Total RNA from Whole Blood for Expression Profiling 3Total RNA from Whole Blood for Expression Profiling 4Total RNA from Whole Blood for Expression Profiling 5Test More siRNAs for Less 2Test More siRNAs for Less 3
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
(Date:5/16/2013)... fast food restaurant had a higher body mass index ... food, according to researchers at The University of Texas ... strong among those with a lower income. , ... Journal of Public Health indicates higher BMI associates ... among lower-income African-Americans, the density, or number, of fast ...
(Date:5/16/2013)... The endothelium, the cellular layer lining the body,s ... few hundred nanometers in thickness, this super-tenuous structure ... tissue compression to create a unique and highly ... partition tissues from the body,s circulatory system. , ... barrier must be physically breached to enable ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... 2008) -- A "chip" or array that can quickly detect ... chromosomal abnormalities proved an effective tool in prenatal diagnosis in ... said researchers in a report that appears in the current ... the report, a team led by Dr. Arthur Beaudet and ...
... Ohio Scientists have identified a relationship between two proteins ... and autism. The finding has led to speculation that existing ... basis for potential therapies to alleviate the symptoms of autism. ... made by the neurexin-1 gene, which is located in brain ...
... illegal in many countries as it can be contaminated ... milk, making it taste bitter and turn thick and ... that can grow at low temperatures, spoiling raw milk ... in the November issue of the International Journal ...
Cached Biology News:Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3Researchers find link between nicotine addiction and autism 2Researchers find link between nicotine addiction and autism 3New bacteria discovered in raw milk 2New bacteria discovered in raw milk 3
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: